Menu Search
Equities

ARCpoint Inc

ARCPF:PKC

ARCpoint Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded160.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 04 2024 16:41 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ARCpoint Inc. is a health care company. The Company provides a United States-based franchise system offering drug testing, alcohol screening, deoxyribonucleic acid (DNA) and clinical lab testing, corporate wellness programs and employment and background screening and other services. Its segments include ARCpoint Franchise, AFG Services, and Other. The ARCpoint Franchise segment includes franchise labs. The AFG Services segment consists primarily of clinical testing and software services that support its franchise systems. This segment also includes diagnostic testing kits sold to franchisees as well as other direct business to business customers. The Other segment consists of corporately held ARCpoint Lab franchises. The Company sells franchises to individuals throughout the United States and provides support in the form of marketing, technology, and training to new franchisees. It develops corporate-owned labs committed to providing solutions for customers, businesses, and physicians.

  • Revenue in CAD (TTM)9.59m
  • Net income in CAD-14.73m
  • Incorporated2022
  • Employees--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.